MAPT and Alzheimer disease: From the clinical to the molecular level, AD is characterized by progressive impairment of cognitive performance, brain atrophy, neuronal and synaptic loss, and pathologic aggregation of amyloid beta (Aβ) and hyperphosphorylated tau (pTau) proteins.